Study on Use of PF-06687234 in Participants with Active Ulcerative Colitis Already Treated with Infliximab Compared with Infliximab Alone
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06687234 as Add-On Therapy to Infliximab in Active Ulcerative Colitis Subjects Who Are Not in Remission (Build UC)
Category & Conditions: Immune System Diseases and Conditions
Medicine: Dekavil
ClinicalTrials.gov Identifier (NCT): NCT03269695
Protocol ID: B7581002
PrintDownloadOpen Plain Language Summary Result: Click here